ReviewVaccines2016
Burkholderia cepacia Complex Vaccines: Where Do We Go from here?
Review in Vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Antibacterial Activity of a Natural Clay Mineral againstMicroorganisms · 2023Article
- Druggable Allosteric Sites in β-Propeller Lectins.Angewandte Chemie (International ed. in English) · 2022Article
- Immunization and Immunotherapy Approaches againstVaccines · 2021Review
- Current Advances inCells · 2020Review
- Article
- Characterization of theVaccines · 2020Article
- Isolation of Arcobacter species and other neglected opportunistic agents from aborted bovine and caprine fetuses.BMC veterinary research · 2019Article
- Article
- Postgenomic Approaches and Bioinformatics Tools to Advance the Development of Vaccines against Bacteria of theVaccines · 2018Review
- Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine.Vaccines · 2017Article
- Vaccines for the Prevention of Melioidosis and Glanders.Current tropical medicine reports · 2017Article
- The art of persistence-the secrets to Burkholderia chronic infections.Pathogens and disease · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia comprises a wide variety of environmental Gram-negative bacteria. Burkholderia cepacia complex (Bcc) includes several Burkholderia species that pose a health hazard as they are able to cause respiratory infections in patients with chronic granulomatous disease and cystic fibrosis. Due to the intrinsic resistance to a wide array of antibiotics and naturally occurring immune evasion strategies, treatment of Bcc infections often proves to be unsuccessful. To date, limited work related to vaccine development has been performed for Bcc pathogens. In this review, we have gathered key aspects of Bcc research that have been reported in recent years related to vaccine efforts, virulence, immune responses, and animal models, and use this information to inform the research community of areas of opportunity toward development of a viable Bcc vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.